Paul E. Marik et al., 2025-08-18: FLCCC/IMA companion protocol guide setting out a limited-therapy and an aggressive-therapy ivermectin dose for cancer. The aggressive schedule is 0.4-0.8 mg/kg/day, commonly 0.6, titrated as tolerated to 1 mg/kg/day.
Ivermectin 0.4-0.8 mg/kg/day (0.6 mg/kg/day). Increase the dose as tolerated up to 1 mg/kg/day if the response is poor.
3
Paul E. Marik et al., 2025-08-18: FLCCC/IMA companion protocol guide setting out a limited-therapy and an aggressive-therapy ivermectin dose for cancer. The aggressive schedule is 0.4-0.8 mg/kg/day, commonly 0.6, titrated as tolerated to 1 mg/kg/day. C3 published protocol. Study type: clinical guidance document, not a study; no patients, no comparator, no funding or conflicts statement printed in the guide. Publisher: FLCCC Alliance, now branded Independent Medical Alliance (IMA); the flccc.net URL redirects to imahealth.org. Doses recorded in full, attributed to the publisher: limited therapy ivermectin 0.2-0.4 mg/kg/day (0.3 mg/kg/day) (p.3, same page); aggressive therapy ivermectin 0.4-0.8 mg/kg/day (0.6 mg/kg/day), 'Increase the dose as tolerated up to 1 mg/kg/day if the response is poor' (p.3); both oral, given with a low-carbohydrate/low-glycemic diet and a multi-drug stack (mebendazole 200 mg daily, doxycycline 50 mg with vitamin C, vitamin D/K2, curcumin, melatonin, metformin, EGCG, propranolol). PDF is 16 pages; quote on p.3. Long-term safety data for this dose and duration: none published as such; the guide states only that a subset of patients 'respond minimally to the initial ivermectin dose, but MAY respond to higher doses' (p.1). Study type: other.
